Study to Determine the Utility of FES-PET in the Prediction of Response to Fulvestrant in Women With Estrogen Positive Metastatic Breast Cancer
NCT03507088
·
clinicaltrials.gov ↗
NA
Phase
COMPLETED
Status
36
Enrollment
OTHER
Sponsor class
Conditions
Metastatic Breast Cancer
Interventions
DRUG:
Fluoroestradiol (18F)
Sponsor
Zhimin Shao